Acutus Medical (NASDAQ:AFIB), a heart device maker focused on arrhythmias, surged ~50% in the pre-market Monday after the company announced the commercial launch of an expanded suite of left-heart access products.
Its product offering now includes the AcQCross Qx system for use with the TruSeal and FXD delivery system for the Watchman LAAC Device, Carlsbad, California-based company said.
“The AcQCross system provides interventional cardiologists and electrophysiologists with unique benefits of broad compatibility with market-leading access sheaths while also enhancing procedure versatility and workflow,” interim Chief Executive of Acutus (AFIB) David Roman remarked.
In April, Acutus (AFIB) shares surged after announcing an agreement with the health equipment maker Medtronic (MDT) to sell its left-heart access portfolio for $50M of upfront cash and milestone-based payments.